Revenue stood at KD 99 million, representing a growth of 6.5% compared to 2023 full-year revenue. The Non-Food Business Line accounted for 34.6% of Group Revenue. The Business Line comprises the ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $180.00. The company’s shares closed last Friday at ...

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted the ire of a pharmaceutical trade organisation that calls the campaign "nothing short ...

The Swiss pharma group is in the throes of a major restructuring exercise since it spun off its Sandoz generics unit last November, which has included job cuts and a narrowing of its R&D focus to ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...